{
  "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
  "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 57,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The chart illustrates the mechanism of action and efficacy of NXC-201 (formerly HBI0101) in treating AL Amyloidosis.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/11",
  "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
  "deckJsonHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3.json",
  "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.5,
        "x": 0.25,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Dual-axis line chart showing HBI0101/mL Blood vs dFLC (mg/L) over Days to CART infusion",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4994b3e8-3dfc-4481-bc6c-ae61c4bbb5a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "*dFLC (=involved FLC-uninvolved FLC). Source: NXC-201 (formerly known as HBI0101). Nexcella ASGCT Presentation Los Angeles 2023...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6421090a-e2fc-4bf4-a019-6b1dddb1e30a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "N-GENIUS Technology Platform – NXC-201 rapidly eliminates diseased AL Amyloidosis plasma cells and exits within ~ 30 days (2/2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f49dc779-911b-4060-819d-52245625f4e3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 11,
      "beatId": "0124f715-f9b4-4df7-a2f6-852908af15ae",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 11,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "db157f78-2fa5-4d70-8683-8c727b29e9dd",
      "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
      "position": 2,
      "objective": "How does NXC-201 perform in clinical trials?",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.8,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}